NA
HAE icon

NewEdge Advisors’s Haemonetics HAE Stock Holding History

NewEdge Advisors’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15
Closed -$1.12K – 4160
2025
Q2 		$1.12K Hold
15
– – ﹤0.01% 3705
2025
Q1 		$953 Hold
15
– – ﹤0.01% 3632
2024
Q4 		$1.17K Hold
15
– – ﹤0.01% 3542
2024
Q3 		$1.21K Hold
15
– – ﹤0.01% 3481
2024
Q2 		$1.24K Hold
15
– – ﹤0.01% 3420
2024
Q1 		$1.28K Hold
15
– – ﹤0.01% 3456
2023
Q4 		$1.28K Buy
+15
New +$1.3K ﹤0.01% 3418
2023
Q3 		– Sell
-4,811
Closed -$410K – 3547
2023
Q2 		$410K Sell
4,811
-147
-3% -$12.4K ﹤0.01% 1287
2023
Q1 		$410K Sell
4,958
-4,557
-48% -$369K 0.01% 1197
2022
Q4 		$491K Sell
9,515
-5,717
-38% -$460K 0.01% 784
2022
Q3 		$1.13M Buy
+15,232
New +$1.09M 0.02% 606

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.82B AUM 7.52% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NewEdge Advisors's HAE Position: Q3 2025 in Review

NewEdge Advisors sold out of Haemonetics (HAE) in Q3 2025, closing a stake of 15 shares — an estimated $1.12K sold.

NewEdge Advisors first reported a position in HAE in Q3 2022 and held it in 11 quarters. The position peaked at $1.13M in Q3 2022. 301 funds tracked by Wall St. Rank hold HAE as of Q3 2025.

  • NewEdge Advisors reported no remaining Haemonetics position as of Q3 2025 after selling out during the quarter.
  • NewEdge Advisors sold 15 Haemonetics shares in Q3 2025, an estimated $1.12K.
  • NewEdge Advisors first reported a position in Haemonetics in Q3 2022 and held it in 11 quarters.
  • NewEdge Advisors's Haemonetics position peaked at $1.13M in Q3 2022.
  • 301 funds tracked by Wall St. Rank held Haemonetics as of Q3 2025.

Based on NewEdge Advisors's 13F filing for Q3 2025, filed 17 Nov 2025.